Alliqua BioMedical Presents at the Spring 2016 SAWC Meeting

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Alliqua BioMedical Presents at the Spring 2016 SAWC Meeting

YARDLEY, Pa., April 12, 2016 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq: ALQA ) ("Alliqua" or "the Company"), a provider of advanced wound care products, will present new cytokine profile data from the analyses of wound fluid and tissue biopsies taken from venous leg ulcers at the Spring 2016 Symposium on Advanced Wound Care, being held at the Georgia World Congress Center in Atlanta, Georgia from April 13 – 17.

The Company will feature a poster summarizing the findings from their InBalance Venous Ulcer prospective, randomized, controlled trial.  The clinical outcomes demonstrated the efficacy of MIST Therapy when used in combination with a good wound care regimen of care.  The study met its primary and secondary endpoints of statistically significant greater percent reduction in ulcer area and number of healed ulcers in those treated with MIST compared to those that received good wound care alone. 1    The cytokine profiles of wound fluid and tissue samples taken from a subset in each treatment group indicate that there is an anti-inflammatory effect from MIST Therapy.  More so, there is an elevation of growth factors that stimulate angiogenesis (new blood vessel growth), which is required for healing wounds.  

During the event, Alliqua will also sponsor two symposia featuring its MIST Therapy ® Systems, Biovance ® , sorbion ® and TheraBond ®  3D products. The first symposium, titled "Comprehensive Approach to Treating Venous Leg Ulcers and Improving Patient Outcomes," will be hosted on Thursday, April 14, and focuses on the treatment of Venous Leg Ulcers highlighting the solutions provided by the Alliqua BioMedical portfolio of products in the control of exudate and bioburden, and promotion of healing. The second, titled “Using an Innovative Ultrasound Technology to Reduce Biofilm and Improve Clinical Outcomes” will be hosted on Friday, April 15 and focuses on a review of the ability of MIST Therapy to destroy biofilms and the extended wound protection from microbes made possible with the use of Alliqua’s wound dressings.   

"The Company’s programming at the Spring 2016 Symposium on Advanced Wound Care meeting demonstrates our dedication to providing not only an increasing portfolio of novel wound care technologies, but also the requisite practitioner education on each technology’s features and benefits,” said Dr. Janice Smiell, Chief Medical Officer of Alliqua. “We are excited to have a faculty of respected clinicians who appreciate Alliqua’s focus on providing advanced wound care solutions to address the challenges presented in the treatment of chronic wounds, especially venous leg ulcers, which are particularly frustrating to both patients and their healthcare providers.” 

About Alliqua BioMedical, Inc.

Alliqua is a provider of advanced wound care solutions, committed to restoring tissue and rebuilding lives. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds. Alliqua currently markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as the sorbion sachet® and sorbion sana® wound care products, and its TheraBond® 3D advanced dressing which incorporates the TheraBond® 3D Antimicrobial Barrier Systems technology. The Company's Mist Therapy® System uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. Alliqua also markets the human biologic wound care product Biovance®.

In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. Alliqua's electron beam production process, located at its 16,500 square foot Good Manufacturing Practice (GMP) manufacturing facility, allows Alliqua to custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. The Company has locations in Yardley, PA, Langhorne, PA and Eden Prairie, MN.

For additional information, please visit http://www.alliqua.com . To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts .

Legal Notice Regarding Forward-Looking Statements:

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, the adequacy of the Company’s liquidity to pursue its complete business objectives; inadequate capital; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in our filings with the SEC, including our most recent Annual Report on Form 10-K filed with the SEC, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov . We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.

1 Gibbons GW, Orgill DP, Serena TE, et al. A Prospective, Randomized, Controlled Trial Comparing the Effects of Noncontact, Low-frequency Ultrasound to Standard Care in Healing Venous Leg Ulcers. Ostomy Wound Management. 2015; 61(1):16-29.

Investor Relations: Westwicke Partners on behalf of Alliqua BioMedical, Inc. Mike Piccinino, CFA +1-443-213-0500 AlliquaBioMedical@westwicke.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 99

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 301

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 116

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 135

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 165

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 156

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading

Top 5 Most Recently Viewed Articles

US LBM Expands Reach with Strategic Milton Truss Acquisition

Updated Category News Views 423

US LBM Welcomes Milton Truss to Its Family US LBM, a leading distributor of specialty building materials, has made a significant move by acquiring Milton Truss, a well-respected manufacturer specializing in structural building components. This acquisition expands US LBM’s operational capabilities and strengthens its presence in the Southeast, particularly within the...

Continue Reading
US Residential Construction Market Shows Promising Growth Ahead

Updated Category News Views 332

The Future of the US Residential Construction Market The residential construction market in the United States is poised to experience significant growth, with estimates suggesting an increase of USD 242.9 million from 2025 to 2029. As household formation rates rise, there is an unmistakable trend towards building more residential units, coupled with an increasing emphasis...

Continue Reading
Orbital Amplifies Currency Reach with Banking Circle

Updated Category News Views 30

Unpacking Orbital's New Alliance with Banking Circle Today's chat's all about payments—specifically how Orbital's rolling out the red carpet with Banking Circle to ramp up their multi-currency payment interface. The company's stretching its limbs into the Nordics, Central Europe, Switzerland, and Australia. With a suit like this, Orbital's not just dropping coins into...

Continue Reading
Jorge Blanco's Achievement Acknowledged as 2025 CRE Tech Influencer

Updated Category News Views 466

Jorge Blanco Celebrated as a 2025 CRE Tech Influencer Altus Group Limited (TSX: AIF), a leading force in asset and fund intelligence for the commercial real estate sector, is excited to announce that its Chief Commercial Officer, Jorge Blanco, has received recognition as a 2025 CRE Technology Influencer. This accolade comes from a renowned publication dedicated to...

Continue Reading
Investor Concerns Rise for Unicycive Therapeutics (UNCY) Amid Investigation

Updated Category News Views 200

Investigating Securities Concerns at Unicycive Therapeutics In the fast-paced world of pharmaceuticals, investor sentiment can shift dramatically based on the health of the company and news that emerges. Currently, Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is facing scrutiny as Pomerantz LLP has initiated an investigation concerning potential claims on behalf of its...

Continue Reading